Close Menu

NEW YORK – Biocept said after the close of the market on Monday that its fourth quarter revenues increased more than tenfold year over year, driven by the precision oncology firm's current provision of COVID-19 testing during the ongoing pandemic.

For the three months ended Dec. 31, 2020, the San Diego-based liquid biopsy test provider reported $18.5 million in total revenues compared to $1.8 million in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.